Abstract: In a method for calculating a B0 field map (a map of the basic magnetic field) in a magnetic resonance apparatus, a navigator pulse is emitted and navigator response resulting from the navigator pulse are detected in at least some channels of a multichannel RF coil array. Each channel of the multichannel RF coil array includes an RF coil and spatial information regarding the respective positions of the individual RF coils is made available to a processor, together with the multiple navigator signals. Using the spatial information obtained from the position of the RF coils that respectively detected the navigator response signals, a B0 field map is generated, without the need for spatial encoding the respective navigator response signals.
Type:
Grant
Filed:
January 23, 2012
Date of Patent:
May 26, 2015
Assignees:
Siemens Aktiengesellschaft, Massachusetts General Hospital Corporation
Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.
Type:
Application
Filed:
May 16, 2013
Publication date:
May 21, 2015
Applicants:
RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
Type:
Application
Filed:
May 16, 2013
Publication date:
May 14, 2015
Applicants:
RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
Abstract: Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided.
Type:
Application
Filed:
May 16, 2013
Publication date:
May 14, 2015
Applicants:
RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.
Type:
Application
Filed:
August 15, 2014
Publication date:
May 14, 2015
Applicants:
President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
David A. Sinclair, Maria Alexander-Bridges
Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
Type:
Application
Filed:
October 26, 2012
Publication date:
April 30, 2015
Applicants:
Millennium Pharmaceuticals, Inc, Massachusetts General Hospital
Inventors:
Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
Abstract: The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Type:
Application
Filed:
September 30, 2014
Publication date:
April 2, 2015
Applicants:
UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
Inventors:
Paul MCCRAY, Morgan MAEDER, Jae Keith JOUNG
Abstract: The present invention provides curcumin-derived near infrared (NIR) imaging probes. Upon interacting with amyloid ? aggregates, these probes undergo a range of changes, qualifying them as “smart” probes. The inventors have demonstrated that probes of the invention have the capacity to monitor the progression of Alzheimer's disease in an in vivo animal model. In addition, the present invention encompasses probes useful as PET imaging agents, MRI imaging agents and multimodal imaging agents, as well as related methods of detecting and imaging amyloid ? aggregates and plaques.
Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
Type:
Application
Filed:
March 14, 2013
Publication date:
March 26, 2015
Applicants:
Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
Inventors:
Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
Abstract: The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, T-cell neoplasms, and cosmetic conditions.
Type:
Application
Filed:
January 11, 2013
Publication date:
February 26, 2015
Applicants:
President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
Malcolm Whitman, Tracy Keller, Ralph Mazitschek
Abstract: Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent ?-amino acid residues in place of a naturally occurring ?-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.
Type:
Application
Filed:
June 23, 2014
Publication date:
December 25, 2014
Applicant:
Massachusetts General Hospital
Inventors:
Samuel H. Gellman, Ross W. Cheloha, Thomas J. Gardella
Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.
Type:
Application
Filed:
August 6, 2014
Publication date:
December 25, 2014
Applicant:
The General Hospital Corporation d/b/a Massachusetts General Hospital
Abstract: Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
October 7, 2014
Assignees:
Ambergen, Inc., Massachusetts General Hospital
Inventors:
Mark J. Lim, Heather P. Ostendorf, Kenneth J. Rothschild, Donald B. Bloch
Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
Type:
Application
Filed:
April 18, 2014
Publication date:
October 2, 2014
Applicants:
Dana Farber Cancer Institute, The General Hospital Corporation d/b/a Massachusetts General Hospital, Beth Israel Deaconess Medical Center
Inventors:
Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
Abstract: The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury.
Type:
Application
Filed:
October 23, 2013
Publication date:
September 25, 2014
Applicant:
The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventors:
Ronald G. TOMPKINS, A. Aria TZIKA, Yong-Ming YU, Laurence RAHME, Jeevendra A. MARTYN
Abstract: The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.
Type:
Grant
Filed:
February 27, 2007
Date of Patent:
September 23, 2014
Assignees:
Massachusetts General Hospital, Metabolon, Inc.
Inventors:
Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan, Kay A. Lawton, Robert Brown, Merit Cudkowicz
Abstract: Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.
Type:
Application
Filed:
December 21, 2011
Publication date:
July 17, 2014
Applicants:
The General Hospital Corporation D/B/A Massachusetts General Hospital, ETHICON ENDO-SURGERY, INC.
Inventors:
Lee M. Kaplan, Nicholas Stylopoulos, Jason L. Harris, Dwight Henninger, Taylor W. Aronhalt, James W. Voegele
Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.
Type:
Application
Filed:
January 2, 2014
Publication date:
July 10, 2014
Applicants:
The General Hospital Corporation dba Massachusetts General Hospital, THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Abstract: The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes.
Type:
Application
Filed:
November 8, 2013
Publication date:
June 19, 2014
Applicants:
The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of Technology
Inventors:
Darrell J. Irvine, Bruce D. Walker, Richard Bradley Jones